Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,434 | 504 | 2,870 |
| Samples | 1,328 | 273 | 1,030 |
| Peptides | 1,171 | 219 | 994 |
Function
ROBO2 · Roundabout guidance receptor 2
The protein encoded by this gene belongs to the ROBO family, part of the immunoglobulin superfamily of proteins that are highly conserved from fly to human. The encoded protein is a transmembrane receptor for the slit homolog 2 protein and functions in axon guidance and cell migration. Mutations in this gene are associated with vesicoureteral reflux, characterized by the backward flow of urine from the bladder into the ureters or the kidney. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 1014 amino-acid changes on canonical ENST00000487694 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ROBO2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ROBO2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| T-Lymphoblastic Leukemia | 6/40 15% | 0/0 0% |
| Melanoma | 26/210 12% | 174/1899 9% |
| Glioblastoma | 8/98 8% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Endometrial Carcinoma | 13/42 31% | 36/612 6% |
| Colorectal Carcinoma | 28/143 20% | 175/3239 5% |
| Non-Small Cell Lung Carcinoma | 33/304 11% | 68/1390 5% |
| Gastric Carcinoma | 16/74 22% | 76/1809 4% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 28/810 3% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Bladder Carcinoma | 9/58 16% | 28/956 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Other Solid Cancers | 5/94 5% | 45/1515 3% |
| Esophageal Carcinoma | 3/23 13% | 21/769 3% |
| Rhabdomyosarcoma | 2/33 6% | 4/171 2% |
| Hepatocellular Carcinoma | 2/46 4% | 61/2210 3% |
| Germ Cell Tumour | 3/25 12% | 2/169 1% |
| Unknown | 1/10 10% | 0/29 0% |
| Osteosarcoma | 4/45 9% | 1/166 1% |
| Ovarian Carcinoma | 14/109 13% | 12/998 1% |
| Hodgkins Lymphoma | 1/16 6% | 2/122 2% |
| B-Cell Non-Hodgkins Lymphoma | 19/88 22% | 37/2534 1% |
| Non-Cancerous | 2/104 2% | 18/830 2% |
| Other Sarcomas | 1/69 1% | 15/699 2% |
| Plasma Cell Myeloma | 3/44 7% | 4/305 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 14/752 2% |
| Head and Neck Carcinoma | 1/85 1% | 26/1574 2% |
| Cervical Carcinoma | 2/35 6% | 4/422 1% |
| Biliary Tract Carcinoma | 2/54 4% | 11/950 1% |
Mutation Distribution
Where ROBO2 is mutated · all tissues, split by cell line vs tissue
How many mutations in ROBO2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,434 mutations in ROBO2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|